Effect of Thrombopoietin on Acute Myelogenous Leukemia Blasts

References

• Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86: 419–431
   PubMed Web of Science ®Google Scholar
• Vigon I., Mornon J.P., Cocault I., Mitjavia M.T., Tambourin P., Gisselbrecht S., Souyri M. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 5640–5644
   PubMed Web of Science ®Google Scholar
• Methia N., Louache F., Vainchenker W., Wendling F. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryopoiesis. Blood 1993; 82: 1395–1401
   PubMed Web of Science ®Google Scholar
• Lok S., Kaushansky K., Holly R.D., Kuijper J.L., Lofton-Day C.E., Oort P.J., Grant F.J., Heipel M.D., Burkhead S.K., Kramer J.M., Bell L.A., Sprecher C.A., Blumberg H., Johnson R., Prunkard D., Ching A.F.T., Mathewes S.L., Bailey M.C., Forstrom J.W., Buddle M.M., Osborn S.G., Evans S.J., Sheppard P.O., Presnell S.R., O'Hara P.J., Hagen F.S., Roth G.J., Foster D.C. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565–568
   PubMed Web of Science ®Google Scholar
• Bartley T.D., Bogenberger J., Hunt P., Li Y.S., Lu H.S., Martin F., Chung M.S., Samal B., Nichol J.L., Swift S., Johnson M.J., Hsu R.Y., Parker V.P., Suggs S., Skrine J.D., Merewether L.A., Clogston C., Hsu E., Hokom M.M., Hornkohl A., Choi E., Pangerinan M., Sun Y., Mar V., McNinch J., Simonet L., Jacobsen F., Xie C., Shutter J., Chute H., Basu R., Selander L., Trollinger D., Sieu L., Padilla D., Trail G., Elliott G., Izumi R., Covey T., Crouse J., Garcia A., Xu W., del Castillo J., Biron J., Cole S., Hu M.C.T., Pacifici R., Ponting I., Saris C., Wen D., Yung Y.P., Lin H., Bosselman R.A. Identification and cloning of a megakaryocyte growth and development factor that is ligand for the cytokine receptor mpl. Cell 1994; 77: 1117–1124
   PubMed Web of Science ®Google Scholar
• de Sauvage F.J., Hass P.E., Spencer S.D., Malloy B.E., Gurney A.L., Spencer S.A., Darbonne W.C., Henzel W.J., Wong S.C., Kuang W.J., Oles K.J., Hultgren B., Solberg L.A., Jr., Goeddel D.V., Eaton D.L. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994; 369: 533–538
   PubMed Web of Science ®Google Scholar
• Kaushansky K., Lok S., Holly R.D., Broudy V.C., Lin N., Bailey M.C., Forstrom J.W., Buddle M.M., Oort P.J., Hagen F.S., Roth G.J., Papayannopoulou T., Foster D.C. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994; 369: 568–571
   PubMed Web of Science ®Google Scholar
• Wendling F., Maraskovsky E., Debili N., Florindo C., Teepe M., Titeux M., Methia N., Breton-Gorius J., Cosman D., Vainchenker W. c-Mpl ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571–574
   PubMed Web of Science ®Google Scholar
• Gurney A.L., Carver-Moor K., de Sauvage F.J., Moore M.W. Thrombocytopenia in c-mpl-deficient mice. Science 1994; 265: 1445–1447
   PubMed Web of Science ®Google Scholar
• de Sauvage F.J., Carver-Moore K., Luoh S.M., Ryan A., Dowd M., Eaton D.L., Moore M.W. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. Journal of Experimental Medicine 1996; 183: 651–656
   PubMed Web of Science ®Google Scholar
• Goncalves F., Lacout C., Villeval J-L., Wendling F., Vainchenker W., Dumenil D. Thrombopoietin does not induce lineage-restricted commitment of mpl-R expressing pluripotent progenitors but permits their complete erythroid and megakaryocytic differentiation. Blood 1997; 89: 3544–3553
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. British Journal of Haematology 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Ben-Bassat I., Gale R.P. Hybrid leukemia. Leukemia Res 1984; 8: 929–936
   PubMed Web of Science ®Google Scholar
• Mirro J., Zipf T.F., Pui C.H., Kitchingman G., Williams D., Melvin S., Murphy S.B., Stass S. Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood 1985; 66: 115–123
   PubMedGoogle Scholar
• McCulloch E.A. Lineage infidelity or lineage promiscuity?. Leukemia 1987; 1: 235
   PubMed Web of Science ®Google Scholar
• Smith L.J., Curtis J.E., Messner H.A., Senn J.S., Furthmayr H., McCulloch E.A. Lineage infidelity in acute leukemia. Blood 1983; 61: 1138–1145
   PubMed Web of Science ®Google Scholar
• Greaves M.F., Chan L.C., Furley A.J.W., Watt S.M., Molgaard H.V. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 1986; 67: 1–11
   PubMed Web of Science ®Google Scholar
• Greaves MF. “Target” cells, cellular phenotypes, and lineage fidelity in human leukaemia. Journal of Cellular Physiology, Supplement 1982; 1: 113–125
   PubMedGoogle Scholar
• Lo Coco F., De Rossi G., Pasqualetti D., Lopez M., Diverio D., Latagliata R., Fenu S., Mandelli F. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. British Journal of Haematology 1989; 73: 480–485
   PubMed Web of Science ®Google Scholar
• Drexler H.G., Thiel E., Ludwig W.D. Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. Leukemia 1993; 7: 489–498
   PubMed Web of Science ®Google Scholar
• Tien H.F., Wang C.H., Su I.J., Liu F.S., Wu H.S., Chen Y.C., Lin K.H., Lee S.C., Shen M.C. A subset of acute nonlymphocytic leukemia with expression of surface antigen CD7 - morphologic, cytochemical, immunocytochemical and T cell receptor gene analysis on 13 patients. Leukemia Research 1990; 14: 515–523
   PubMed Web of Science ®Google Scholar
• Tien H.F., Chou C.C., Wang C.H., Chang C.H., Hsing C.C. Putative normal counterparts of leukaemic cells from CD7-positive acute myeloid leukaemia can be demonstrated in human haemopoietic tissues. British Journal of Haematology 1996; 94: 501–506
   PubMed Web of Science ®Google Scholar
• Eto T., Akashi K., Harada M., Shibuya T., Takamatsu Y., Teshima T., Niho Y. Biological characteristics of CD7 positive acute myelogenous leukaemia. British Journal of Haematology 1992; 82: 508–514
   PubMed Web of Science ®Google Scholar
• Kita K., Miwa H., Nakase K., Kawakami K., Kobayashi T., Shirakawa S., Tanaka I., Ohta C., Tsutani H., Oguma S., Kyo T., Dohy H., Kamada N., Nasu K., Uchino H. Clinical importance of CD7 expression in acute myelocytic leukemia. Blood 1993; 81: 2399–2405
   PubMed Web of Science ®Google Scholar
• Matsumura I., Kanakura Y., Kato T., Ikeda H., Ishikawa J., Horikawa Y., Hashimoto K., Moriyama Y., Tsujimura T., Nishiura T., Miyazaki H., Matsuzawa Y. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood 1995; 86: 703–709
   PubMed Web of Science ®Google Scholar
• Motoji T., Takanashi M., Motomura S., Yan-Hua W., Shiozaki H., Aoyama M., Mizoguchi H. Growth stimulatory effect of thrombopoietin on the blast cells of acute myelogenous leukaemia. British Journal of Haematology 1996; 94: 513–516
   PubMed Web of Science ®Google Scholar
• Akashi K., Harada M., Shibuya T., Eto T., Takamatsu Y., Teshima T., Niho Y. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34− blasts from acute myelogenous leukemia. Blood 1991; 78: 197–204
   PubMed Web of Science ®Google Scholar
• Miyamoto T., Nagafuji K., Akashi K., Harada M., Kyo T., Akashi T., Takenaka K., Mizuno S., Gondo H., Okamura T., Dohy H., Niho Y. Persistence of multipotent progenitors expressing AMLI/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789–4796
   PubMed Web of Science ®Google Scholar
• Horikawa Y., Matsumura I., Hashimoto K., Shiraga M., Kosugi S., Tadokoro S., Kato T., Miyazaki H., Tomiyama Y., Kurata Y., Matsuzawa Y., Kanakura Y. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood 1997; 90: 4031–4038
   PubMed Web of Science ®Google Scholar
• Wetzler M., Baer M.R., Bernstein S.H., Blumenson L., Stewart C., Barcos M., Mrozek K., Block A.W., Herzig G.P., Bloomfield C.D. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. Journal of Clinical Oncology 1997; 15: 2262–2268
   PubMed Web of Science ®Google Scholar
• Takeshita A., Shinjo K., Izumi M., Ling P., Nakamura S., Naito K., Ohnishi K., Ohno R. Quantitative expression of thrombooietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. British Journal of Haematology 1998; 100: 283–290
   PubMed Web of Science ®Google Scholar
• Ulich T.R., Del Castillo J., Yin S., Swift S., Padilla D., Senaldi G., Bennett L., Shutter J., Bogenberger J., Sun D., Samal B., Shimamoto G., Lee R., Steinbrink R., Boone T., Sheridan W.T., Hunt P. Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood 1995; 86: 971–976
   PubMed Web of Science ®Google Scholar
• Hokom M.M., Lacey D., Kinstler O.B., Choi E., Kaufman S., Faust J., Rowan C., Dwyer E., Nichol J.L., Grasel T., Wilson J., Steinbrink R., Hecht R., Winters D., Boone T., Hunt P. Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood 1995; 86: 4486–4492
   PubMed Web of Science ®Google Scholar
• Basser R.L., Rasko J.E.J., Clarke K., Cebon J., Green M.D., Hussein S., Alt C., Menchaca D.M., Tomita D., Marty J., Fox R.M., Begley C.G. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348: 1279–1281
   PubMed Web of Science ®Google Scholar
• Basser R.L., Rasko J.E.J., Clarke K., Cebon J., Green M.D., Grigg A.P., Zalcberg J., Cohen B., O'Byrne J., Menchaca D.M., Fox R.M., Begley C.G. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advance cancer. Blood 1997; 89: 3118–3123
   PubMed Web of Science ®Google Scholar
• Rasko J.E.J., Basser R.L., Boyd J., Mansfield R., O'Malley C.J., Hussein S., Berndt M.C., Clarke K., O'Byrne J., Sheridan W.P., Grigg A.P., Begley C.G. Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. British Journal of Haematology 1997; 97: 871–880
   PubMed Web of Science ®Google Scholar
• Geller R.B. Use of cytokines in the treatment of acute myelocytic leukemia: clinical review. Journal of Clinical Oncology 1996; 14: 1155–1160
   Google Scholar
• Geissler K., Kabrna E., Stengg S., Schwarzinger I., Knobl Paul, Valent P., Eichinger S., Barge A., Lechner K. Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemothrapy in patients with acute myeloid leukaemia. British Journal of Haematology 1998; 102: 535–543
   PubMed Web of Science ®Google Scholar